Antibodies and Polypeptides Specific to AAMP-1: Diagnostic and Therapeutic Uses Thereof
Description of Invention:
Angio-associated migratory cell protein (AAMP-1) was first isolated from a human melanoma cell line as a motility-associated cell protein. AAMP-1 contains two immunoglobin domains, six WD40 repeats, and a heparin-binding domain. In vitro, over expression of AAMP-1 promotes tumor cell invasion and metastasis as well as angiogenesis. AAMP-1 was later found to be over expressed in endothelial cells, cytotrophoblasts, and poorly differentiated colon adenocarcinoma cells found in lymphatics. In addition, gene expression studies have shown that AAMP-1 is over expressed in breast and gastrointestinal tumors. The issued patents claim proteins, polypeptides, and recombinant polyclonal antibodies specific to AAMP-1 and their use in diagnostic and therapeutic applications.
Applications:
The antibodies specific to AAMP-1 can detect formalin-fixed antigen and SDS-denatured antigen. These antibodies can be used for detailed expression studies of AAMP-1 in different cancer cell lines.
The antibodies could also be used to detect AAMP-1 in patient's sera as a useful diagnostic marker for multiple carcinomas including high nuclear grade ductal carcinoma in situ (Clinical Cancer Research Dec 2002 8:3788-95).
Claimed proteins and polypeptides could also be used to promote cell adhesion to a substrate, promote tissue acceptance of prostheses, and promote wound healing.
Development Status:
This technology is currently in the pre-clinical stage of development.
Market:
Estimated new cases and deaths from breast cancer in the United States in 2007 --
New cases: 178,480 (female); 2,030 (male)
Deaths: 40,460 (female); 450 (male)
Inventors:
Marie Beckner (NCI) Henry Krutzsch (NCI) Lance Liotta (NCI)
Patent Status:
DHHS Reference No. E-084-1991/1 --
U.S. Patent No. 6,274,134 issued 14 Aug 2001
Australian Patent No. 684,806 issued 23 Apr 1998
Japanese Patent No. 3,715,313 issued 09 Nov 2005
ME Beckner et al. AAMP, a newly identified protein, shares a common epitope with alpha-actinin and a fast skeletal muscle fiber protein. Exp Cell Res. 1996 Jun 15;225(2):306-314. [PubMed abs]
A Adeyinka et al. Analysis of gene expression in ductal carcinoma in situ of the breast. Clin Can Res. 2002 Dec;8(12):3788-3795. [PubMed abs]
Licensing Status: Available for exclusive or non-exclusive licensing.
Portfolios: Cancer
Cancer -Therapeutics-Biological Response Modifiers Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: Surekha Vathyam Ph.D.
Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4076
Email: vathyams@mail.nih.gov
Fax: 301/402-0220
